Micronaute Competitors

As a society we’ve always dreamt of a healthy, disease-free world. One of the bravest moves in that direction has come from stem cell research and therapy. Stem cell therapy is currently being used to successfully treat more than 80 diseases, but we think there’s still a long way to go. Smart Cells is the first private UK stem cell storage company to have released stored stem cell units for use in the treatment of children with life-threatening illnesses. We have released the greatest number of samples for use in successful transplants in the UK. We believe with the development of technology in the future we will be able to treat even more illnesses, and we’re working on it. We believe our customers deserve the best service available and we staff our state of the art facility with the top professionals in the field. We believe that storing your child’s stem cells at birth can be a crucial part of curing an unexpected illness. We believe that in the future this service should be available to every parent, child and family. We are a company that is for life.

Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers. Our clinical stage drug candidate, CB-103, has demonstrated both safety and biological activity in humans. Along with ongoing Phase 2 IITs for multi-drug resistant cancers, CB-103 is also poised to enter a Proof-of-Concept clinical study for graft-versus-host disease (GvHD)

The mission of Crescendo Bioscience, Inc. is to enable more effective management of autoimmune and inflammatory diseases by providing quantitative, objective molecular tests and disease information services to rheumatologists and patients. Crescendo Bioscience is currently focused on rheumatoid arthritis (RA), a debilitating, chronic disease affecting over 1.5 million people in the United States and more than 2 million in Europe. Although there is no known cure for RA, multiple therapies are available, with widely differing levels of effectiveness and significant potential toxicities. Choosing the optimal treatment from among these therapeutic alternatives is a tremendous challenge. At Crescendo Bioscience, we are committed to improving rheumatologists’ ability to understand the biology underlying RA and to better determine the status of a patient’s disease. Vectra® DA is the first and only multi-biomarker blood test validated to measure RA disease activity. Vectra DA integrates the concentrations of 12 serum proteins associated with RA disease activity into a single objective score to help physicians make more informed treatment decisions. Crescendo Bioscience has also developed MyRA™, a free mobile app for people living with RA which was designed to empower patients to regularly track multiple aspects (e.g. medications, morning stiffness, joint pain, daily functionality, etc.) of their RA and easily share the information with their physician.